MSFT, BABA, and MRK headline today's top analyst picks, with AI, global e-commerce, and oncology driving mixed growth stories ...

China’s vaccine landscape is shifting after local biotech Xiamen Innovax Biotech unveiled the country’s first domestically ...

MSFT, BABA, and MRK lead today's top analyst picks, with AI, e-commerce, and cancer drug strategies in sharp focus.

Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

A Chinese drug regulator approved a new homegrown vaccine against cervical cancer, fueling further competition against Merck & Co Ltd.’s blockbuster shot Gardasil in the world’s second-largest ...

Merck’s stock tumbled early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset better-than-expected fourth-quarter earnings.

Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations, as the company temporarily paused shipments of a key vaccine into China. Shares of Merck ...

The company said that sales range reflects a decision to halt shipments of Gardasil, a vaccine that prevents cancer from HPV, into China beginning in February and going through at least mid-2025.